Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
1.710
-0.290 (-14.50%)
At close: Nov 13, 2026, 4:00 PM EST
1.700
-0.010 (-0.58%)
After-hours: Nov 13, 2026, 7:56 PM EST
Adagene Revenue
Adagene had revenue of $1.62M in the half year ending June 30, 2026. This brings the company's total for the last twelve months to $9.29M, up 8,902.38% year-over-year. In the year 2025, Adagene had annual revenue of $7.67M with 7,332.76% growth. That makes Adagene the 37,701st largest company in the world by revenue and 4,943rd in the United States.
Revenue (ttm)
$9.29M
Revenue Growth
+8,902.38%
P/S Ratio
12.36
Revenue / Employee
$72,584
Employees
128
Market Cap
114.82M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.67M | 7.57M | 7,332.76% |
| Dec 31, 2024 | 103.20K | -18.01M | -99.43% |
| Dec 31, 2023 | 18.11M | 8.82M | 94.90% |
| Dec 31, 2022 | 9.29M | -882.53K | -8.67% |
| Dec 31, 2021 | 10.18M | 9.47M | 1,351.71% |
| Dec 31, 2020 | 700.91K | 220.91K | 46.02% |
| Dec 31, 2019 | 480.00K | -1.03M | -68.24% |
| Dec 31, 2018 | 1.51M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Foghorn Therapeutics | 112.13M |
| Codexis | 88.34M |
| Cue Biopharma | 37.66M |
| Voyager Therapeutics | 25.11M |
| Innate Pharma | 11.21M |
| Molecular Partners AG | 856.30K |
| Spruce Biosciences | 697.00K |
ADAG News
- 4 days ago - Adagene Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 4 days ago - Adagene completes enrollment in muzastotug trial - TheFly
- 4 days ago - Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - GlobeNewsWire
- 16 days ago - Adagene doses first patient in muzastotug, INCA33890 combination study - TheFly
- 16 days ago - Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer - GlobeNewsWire
- 17 days ago - Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference - GlobeNewsWire
- 24 days ago - Adagene Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 4 weeks ago - Adagene Transcript: H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference - Transcripts